首页> 外文OA文献 >Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

【2h】

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

机译：Bevacizumab与多西紫杉醇，奥沙利铂和Capecitabine相结合，然后用Capecitabine和Bevacizumab进行维持，作为高级Her2阴性胃癌患者的一线治疗：多中心2研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Didier Meulendijks; Jan Willem B. de Groot; Maartje Los; James E. Boers; Laurens V. Beerepoot; Marco B. Polee; Aart Beeker; Johanna E.A. Portielje; Swan H. Goey; Robert S. de Jong; Steven A.L.W. Vanhoutvin; Maria Kuiper; Karolina Sikorska; Dick Pluim; Jos H. Beijnen; Jan H.M. Schellens; Cecile Grootscholten; Margot E.T. Tesselaar; Annemieke Cats;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study [J] . Meulendijks Didier, de Groot Jan Willem B., Los Maartje, Cancer: A Journal of the American Cancer Society . 2016,第9期

机译：贝伐单抗联合多西他赛，奥沙利铂和卡培他滨，然后维持卡培他滨和贝伐单抗作为晚期HER2阴性胃癌患者的一线治疗：一项多中心2期研究
2. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study [J] . Meulendijks Didier, Beerepoot Laurens V., Boot Henk, Investigational new drugs. . 2016,第1期

机译：曲妥珠单抗和贝伐单抗联合多西他赛，奥沙利铂和卡培他滨作为一线治疗晚期HER2阳性胃癌的多中心II期研究
3. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): A randomised, open-label, phase 3 trial [J] . GligorovJ., DovalD., BinesJ., The lancet oncology . 2014,第12期

机译：HER2阴性转移性乳腺癌（IMELDA）患者初始一线贝伐单抗和多西他赛治疗后维持卡培他滨和贝伐单抗与单独使用贝伐单抗的比较：一项随机，开放标签的3期临床研究
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter randomized phase III trial [O] . Christoph Rochlitz, Martin Bigler, Roger von Moos, 2016

机译：SAKK 24/09：贝伐单抗联合紫杉醇与贝伐单抗联合节律性环磷酰胺和卡培他滨作为HER2阴性晚期乳腺癌患者的一线治疗的安全性和耐受性-多中心随机III期研究
7. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. [O] . Rochlitz, C., Bigler, M., von Moos, R., 2016

机译：SAKK 24/09：贝伐单抗联合紫杉醇与贝伐单抗联合节律性环磷酰胺和卡培他滨作为HER2阴性晚期乳腺癌患者的一线治疗的安全性和耐受性-多中心，随机，III期试验。

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

著录项

相似文献

相关主题

期刊订阅